Table 4

Multivariate analysis for factors associated with survival after surgery for femur metastasis

FactorsOdds ratio (95% CI)p value
Cancer type<.001a
 Favorable.416 (0.27–0.63)
 UnfavorableRef
Metastasis.001a
 Single.527 (0.36–0.76)
 MultipleRef
Fracture type.01a
 Impending.670 (0.49–0.90)
 CompleteRef
Type of surgery.047a
 Endoprosthesis.731 (0.53–0.99)
 Internal fixationRef
Ambulation recovery<.001a
 Recovered.477 (0.32–0.69)
 FailedRef
Premorbid ECOG.003a
 Favorable.572 (0.39–0.82)
 UnfavorableRef
FactorsOdds ratio (95% CI)p value
Cancer type<.001a
 Favorable.416 (0.27–0.63)
 UnfavorableRef
Metastasis.001a
 Single.527 (0.36–0.76)
 MultipleRef
Fracture type.01a
 Impending.670 (0.49–0.90)
 CompleteRef
Type of surgery.047a
 Endoprosthesis.731 (0.53–0.99)
 Internal fixationRef
Ambulation recovery<.001a
 Recovered.477 (0.32–0.69)
 FailedRef
Premorbid ECOG.003a
 Favorable.572 (0.39–0.82)
 UnfavorableRef

aStatistically significant.

Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; Ref, reference.

Table 4

Multivariate analysis for factors associated with survival after surgery for femur metastasis

FactorsOdds ratio (95% CI)p value
Cancer type<.001a
 Favorable.416 (0.27–0.63)
 UnfavorableRef
Metastasis.001a
 Single.527 (0.36–0.76)
 MultipleRef
Fracture type.01a
 Impending.670 (0.49–0.90)
 CompleteRef
Type of surgery.047a
 Endoprosthesis.731 (0.53–0.99)
 Internal fixationRef
Ambulation recovery<.001a
 Recovered.477 (0.32–0.69)
 FailedRef
Premorbid ECOG.003a
 Favorable.572 (0.39–0.82)
 UnfavorableRef
FactorsOdds ratio (95% CI)p value
Cancer type<.001a
 Favorable.416 (0.27–0.63)
 UnfavorableRef
Metastasis.001a
 Single.527 (0.36–0.76)
 MultipleRef
Fracture type.01a
 Impending.670 (0.49–0.90)
 CompleteRef
Type of surgery.047a
 Endoprosthesis.731 (0.53–0.99)
 Internal fixationRef
Ambulation recovery<.001a
 Recovered.477 (0.32–0.69)
 FailedRef
Premorbid ECOG.003a
 Favorable.572 (0.39–0.82)
 UnfavorableRef

aStatistically significant.

Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; Ref, reference.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close